JobeA.Surfactant treatment for respiratory distress syndrome. Respir Care1986;31(6):467–476.
2.
BerryD.Neonatology in the 1990's: surfactant replacement therapy becomes a reality. Clin Pediatr1991;30(3):167–170.
3.
AveryME, MeadJ.Surface properties in relation to atelectasis and hyaline membrane disease. Am J Dis Child1959;97:517–523.
4.
von NeergardK.Neue Auffassungen über einen Grundbegriff der Atemmechanik: die Retraktionskraft der Lunge, äbhangig von der Oberflächenspannung in den Alveolen. Z Ges Exp Med1929;66:373.
StablemanMT.Acute respiratory disorders in the newborn. In: AveryG, ed. Neonatology. Philadelphia: JB Lippincott, 1975:221–249.
7.
HorbarJD, WrightEC, OnstadL.Decreasing mortality associated with the introduction of surfactant therapy: an observational study of neonates weighing 601 to 1300 grams at birth. Pediatrics1993;92(2):191–196.
8.
LangMJ, HallRT, ReddyNS, KurthCG, MerrittTA.A controlled trial of human surfactant replacement therapy for severe respiratory distress syndrome in very low birth weight infants. J Pediatr1990;116(2):295–300.
9.
HoekstraRE, JacksonJC, MyersTF, FrantzIDIII, SternME, PowersWF, .Improved neonatal survival following multiple doses of bovine surfactant in very premature neonates at risk for respiratory distress syndrome. Pediatrics1991;88(1):10–18.
10.
KattwinkelJ, BloomBT, DelmoreP, DavisCL, FarrellE, FrissH, .Prophylactic administration of calf lung surfactant extract is more effective than early treatment of respiratory distress syndrome in neonates of 29 through 32 weeks' gestation. Pediatrics1993;92(1):90–98.
11.
MerrittTA, HallmanM, BerryC, PohjavuoriM, EdwardsDK, JaaskelainenJ, .Randomized, placebo-controlled trial of human surfactant given at birth versus rescue administration in very low birth weight infants with lung immaturity. J Pediatr1991;118(4):581–594.
12.
DunnMS, ShennanAT, ZayackD, PossmayerF.Bovine surfactant replacement therapy in neonates of less than 30 weeks' gestation: a randomized controlled trial of prophylaxis versus treatment. Pediatrics1991;87(3):377–386.
13.
LongW, ThompsonT, SundellH, SchumacherR, VolbergF, GuthrieR, .Effects of two rescue doses of a synthetic surfactant on mortality rate and survival without bronchopulmonary dysplasia in 700 to 1350-gram infants with respiratory distress syndrome. J Pediatr1991;118(4):595–605.
14.
LiechtyEA, DonovanE, PurohitD, GilhoolyJ, FeldmanB, NoguchiA, .Reduction of neonatal mortality after multiple doses of bovine surfactant in low birth weight neonates with respiratory distress syndrome. Pediatrics1991;88(1):19–28.
15.
LongW, CorbetA, CottonR, CourtneyS, Mc GuinessG, WalterD, .A controlled trial of synthetic surfactant in infants weighing 1250 g or more with respiratory distress syndrome. N Engl J Med1991;325(24):1696–1703.
16.
FujiwaraT., KonishiM., ChidaS., OkuyamaK., OgawaY., TakecuchiY., .Surfactant replacement therapy with a single postventilatory dose of a reconstituted bovine surfactant in preterm neonates with respiratory distress syndrome: final analysis of a multicenter, double-blind, randomized trial and comparison with similar trials. Pediatrics1990;86(5):753–764.
17.
The OSIRIS Collaborative Group. Early versus delayed neonatal administration of a synthetic surfactant-the judgement of OSIRIS. Lancet1992;340(8832):1363–1369.
18.
FerraraTB, HoekstraRE, CouserRJ, GazianoEP, CalvinSE, PayneNR, .Survival and follow-up of infants born at 23 to 26 weeks of gestational age: effects of surfactant therapy. J Pediatr1994;124(1):119–124.
19.
HallmanM, MerrittTA, JarvenpaaA-L, BoyntonB, ManninoF, GluckL, .Exogenous human surfactant for treatment of severe respiratory distress syndrome: a randomized prospective clinical trial. J Pediatr1985;106(6):963–969.
20.
BerryDD, PramanikAK, PhillipsJBIII, BuchterDS, KanarekKS, EasaD, .Comparison of the effect of three doses of a synthetic surfactant on the alveolar-arterial oxygen gradient in infants weighing ≥ 1250 grams with respiratory distress syndrome. J Pediatr1994;124(2):294–301.
21.
GortnerL, BartmannP, PohlandtF, BernsauU, PorzF, HellwegeHH, .Early treatment of respiratory distress syndrome with bovine surfactant in very preterm infants: a multicenter controlled clinical trial. Pediatr Pulmonol1992;14(1):4–9.
22.
CorbetAJ, LongWA, MurphyDJ, Garcia-PratsJA, LombardyLR, WoldDE.Reduced mortality in small premature infants treated at birth with a single dose of synthetic surfactant. J Paediatr Child Health1991;27(4):245–249.
23.
BoseC, CorbetA, BoseG, Garcia-PratsJ, LombardyL, WoldD, .Improved outcome at 28 days of age for very low birth weight infants treated with a single dose of a synthetic surfactant. J Pediatr1990;117:947–953.
24.
CorbetA, BucciarelliR, GoldmanS, MammelM, WoldD, LongW, American Exosurf Pediatric Study Group. Decreased mortality rate among small premature infants treated at birth with a single dose of synthetic surfactant: a multicenter controlled trial. J Pediatr1991;118(2):277–284.
25.
MerrittTA, HallmanM, BloomBT, BerryC, BenirschkeK, SahnD, .Prophylactic treatment of very premature infants with human surfactant. N Engl J Med1986;315(13):785–790.
26.
KendigJW, NotterRH, CoxC, ReubensLJ, DavisJM, ManiscalcoWM, .A comparison of surfactant as immediate prophylaxis and as rescue therapy in newborns of less than 30 weeks' gestation. N Engl J Med1991;324(13):865–871.
27.
EgbertsJ, de WinterJP, SedinG, deKleineMJ, BrobergerU, van BelF, .Comparison of prophylaxis and rescue treatment with Curosurf in neonates less than 30 weeks' gestation: a randomized trial. Pediatrics1993;92(6):768–774.
28.
SollRF, HoekstraRE, FangmanJJ, CorbetAJ, AdamsJM, JamesLS, .Multicenter trial of single-dose modified bovine surfactant extract (Survanta) for prevention of respiratory distress syndrome. Pediatrics1990;85(6):1092–1102.
29.
HeldtGP, PesonenE, MerrittTA, EliasW, SahnDJ.Closure of the ductus arteriosus and mechanics of breathing in preterm infants after surfactant replacement therapy. Pediatr Res1989;25(3):305–310.
30.
HallmanM, MerrittTA, BryK, BerryC.Association between neonatal care practices and efficacy of exogenous human surfactant: results of a bicenter randomized trial. Pediatrics1992;91(3):552–560.
31.
LotzeA, KnightGR, MartinGR, BulasDI, HullWM, O'DonnellRM, .Improved pulmonary outcome after exogenous surfactant therapy for respiratory failure in term infants requiring extracorporeal membrane oxygenation. J Pediatr1993;122(2):261–268.
32.
RajuTN, LangenbergP.Pulmonary hemorrhage and exogenous surfactant therapy: a meta-analysis. J Pediatr1993;123(4):603–610.
33.
HorbarJD, SollRF, SutherlandJM, KotagalU, PhilipAGS, KesslerDL, .A multicenter randomized, placebo-controlled trial of surfactant therapy for respiratory distress syndrome. N Engl J Med1989;320(15):959–965.
34.
HorbarJD, WrightLL, SollRF, FanaroffAA, KoronesSB, ShankaranS, .A multicenter randomized trial comparing two surfactants for the treatment of neonatal respiratory distress syndrome. J Pediatr1993;123(5):757–766.
35.
HazanJ, ChessexP, PiedboeufB, BourgeoisM, BardH, LongW.Energy expenditure during synthetic surfactant replacement therapy for neonatal respiratory distress syndrome. J Pediatr1992;120(2, Part 2):S29–S33.
36.
SpeerCP, HarmsK, HertingE, NeumannN, CurstedtT, RobertsonB.Early versus late surfactant replacement therapy in severe respiratory distress syndrome. Lung1990;168(Suppl):870–876.
37.
KhammashH, PerlmanM, WojtulewiczJ, DunnM.Surfactant therapy in full-term neonates with severe respiratory failure. Pediatrics1993;92(1):135–139.
38.
StevensonD, WaltherF, LongW, SellM, PaulT, GongA, .Controlled trial of a single dose of synthetic surfactant at birth in premature infants weighing 500 to 699 grams. J Pediatr1992;120(2, Part 2):S3–S12.
39.
DunnMS, ShennanAT, PossmayerF.Single- versus multiple-dose surfactant replacement therapy in neonates of 30 to 36 weeks' gestation with respiratory distress syndrome. Pediatrics1990;86(4):564–571.
40.
Hellstrom-WestasL, BellAH, SkovL, GreisenG, SvenningsenNW.Cerebroelectrical depression following surfactant treatment in preterm neonates. Pediatrics1992;89(4):643–647.
41.
ZolaEM, GunkelJH, ChanRK, LimMO, KnoxI, FeldmanBH, .Comparison of three dosing procedures for administration of bovine surfactant to neonates with respiratory distress syndrome. J Pediatr1992;122(3):453–459.
42.
AnnibaleDJ, HulseyTC, WallinLA, EngstromPC.Clinical diagnosis and management of respiratory distress in preterm neonates: effect of participation in a controlled trial. Pediatrics1992;90(3):397–400.
43.
GoldmanSL, BosqueE, McCannE, LewisK.Pulmonary mechanics in premature infants one month after treatment with synthetic surfactant. J Pediatr1992;120(2, Part 2):S25–S28.
44.
SpeerCP, RobertsonB, CurstedtT, HallidayHL, CompagnoneD, GefellerO, .Randomized European multicenter trial of surfactant replacement therapy for severe neonatal respiratory distress syndrome: single versus multiple doses of Curosurf. Pediatrics1992;89(1):13–20.
45.
GunkelJH, BanksPL.Surfactant therapy and intracranial hemorrhage: review of the literature and results of new analyses. Pediatrics1993;92(6):775–786.
46.
ZolaEM, OverbachAM, GunkelJH, MitchellBR, NagleBT, DeMarcoNG, .Treatment investigational new drug experience with Survanta (beractant). Pediatrics1993;91(3):546–551.
47.
van HoutenJ, LongW, MullettM, FinerN, DerlethD, McMurrayB, .Pulmonary hemorrhage in premature infants after treatment with synthetic surfactant: an autopsy evaluation. J Pediatr1992;120(2, Part 2):S40–S44. Erratum appears in J Pediatr 1992;120(5):762.
48.
RubinBK, RamirezO, KingM.Mucus rheology and transport in neonatal respiratory distress syndrome and the effect of surfactant therapy. Chest1992;101(4):1080–1085.
49.
GoldsmithLS, GreenspanJS, RubensteinSD, WolfsonMR, ShafferTH.Immediate improvement in lung volume after exogenous surfactant: alveolar recruitment versus increased distention. J Pediatr1991;119(3):424–428.
50.
BhutaniVK, AbbasiS, LongWA, GerdesJS.Pulmonary mechanics and energetics in preterm infants who had respiratory distress syndrome treated with synthetic surfactant. J Pediatr1992;120(2, Part 2):S18–S24.
51.
BhatR, DziedzicK, BhutaniVK, VidyasagarD.Effect of single dose surfactant on pulmonary function. Crit Care Med1990;18(6):590–595.
52.
AbbasiS, BhutaniVK, GerdesJS.Long-term pulmonary consequences of respiratory distress syndrome in preterm infants treated with exogenous surfactant. J Pediatr1993;122:446–452.
53.
DavisJM, Veness-MeehanK, NotterRH, BhutaniVK, KendigJW, ShapiroDL.Changes in pulmonary mechanics after the administration of surfactant to infants with respiratory distress syndrome. N Engl J Med1988;319(8):476–479.
54.
ArmsbyDH, BellonG, CarlisleK, RectorD, BaldwinR, StevensonDK, .Delayed compliance increase in infants with respiratory distress syndrome following synthetic surfactant. Pediatr Pulmonol1992;14(4):206–213.
55.
CouserRJ, FerraraTB, EbertJ, HoekstraRE, FangmanJJ.Effects of exogenous surfactant therapy on dynamic compliance during mechanical breathing in preterm infants with hyaline membrane disease. J Pediatr1990;116(1):119–124.
56.
SvenningsenNW, BjorklundL, VilstrupC, WernerO.Lung mechanics (FRC and static pressure-volume diagram) after endotracheal surfactant instillation: preliminary observations. Biol Neonate1992;61(Suppl 1):44–47.
57.
PfenningerJ, AebiC, BachmannD, WagnerBP.Lung mechanics and gas exchange in ventilated preterm infants during treatment of hyaline membrane disease with multiple doses of artificial surfactant (Exosurf). Pediatr Pulmonol1992;14(1):10–15.
58.
KellyE, BryanH, PossmayerF, FrndovaH, BryanC.Compliance of the respiratory system in newborn infants pre- and postsurfactant replacement therapy. Pediatr Pulmonol1993;15(4):225–230.
59.
YukselB, GreenoughA, GamsuHR.Respiratory function at follow-up after neonatal surfactant replacement therapy. Respir Med1993;87(3):217–221.
60.
KääpäP, SeppanenM, KeroP, SarasteM.Pulmonary hemodynamics after synthetic surfactant replacement in neonatal respiratory distress syndrome. J Pediatr1993;123(1):115–119.
61.
SitlerCG, TurnageCS, McFaddenBE, SmithEO, AdamsJM.Pump administration of exogenous surfactant: effects on oxygenation, heart rate, and chest wall movement of premature infants. J Perinatol1993;13(3):197–200.
62.
Centers for Disease Control. Update: Universal Precautions for prevention of transmission of human immunodeficiency virus, hepatitis B virus, and other blood-borne pathogens in health-care settings. MMWR1988;37:377–382,387–388.
